Symbols

ACAD

Acadia Pharmaceuticals·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Gap Down

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ACAD

Acadia Pharmaceuticals Inc.

A biopharmaceutical company that developing medicines for central nervous system disorders

Industry

Biological Technology

Established Date

Listing Date

05/27/2004

Exchange

NASDAQ Stock Exchange

Full-time Employees

796

Fiscal Year Ends

12-31

Website

www.acadia.com

Security Type

Common stock

Office address

12830 El Camino Real, Suite 400, San Diego, California 92130

Business

Introduction

Acadia Pharmaceuticals Inc., originally incorporated in Vermont in 1993, was re-incorporated in Delaware in 1997. Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative micromolecular drugs to address unmet medical needs in neurological and central nervous system diseases. The company has two core businesses in neurological diseases and rare diseases. The core product of its neurological disease business is the marketed NUPLAZID (Pimo Panserin), which is the first and currently the only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions related to Parkinson's disease psychosis (PDP). The core product of its rare disease business is the marketed DAYBUE, which is the first and currently the only drug approved for the treatment of Rett syndrome. In addition to these marketed products, the company has a portfolio of product candidates and research programs designed to address significant unmet medical needs in the field of neurological diseases and rare diseases.

Company Financials

EPS

ACAD has released its 2025 Q4 earnings. EPS was reported at 0.14, versus the expected 0.13, beating expectations. The chart below visualizes how ACAD has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ACAD has released its 2025 Q4 earnings report, with revenue of 283.99M, reflecting a YoY change of 9.39%, and net profit of 273.57M, showing a YoY change of 90.32%. The Sankey diagram below clearly presents ACAD's revenue sources and cost distribution.